Jennifer S. Graff

699 total citations
35 papers, 487 citations indexed

About

Jennifer S. Graff is a scholar working on Economics and Econometrics, General Health Professions and Geriatrics and Gerontology. According to data from OpenAlex, Jennifer S. Graff has authored 35 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Economics and Econometrics, 11 papers in General Health Professions and 7 papers in Geriatrics and Gerontology. Recurrent topics in Jennifer S. Graff's work include Health Systems, Economic Evaluations, Quality of Life (30 papers), Pharmaceutical Practices and Patient Outcomes (7 papers) and Medication Adherence and Compliance (6 papers). Jennifer S. Graff is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (30 papers), Pharmaceutical Practices and Patient Outcomes (7 papers) and Medication Adherence and Compliance (6 papers). Jennifer S. Graff collaborates with scholars based in United States, Switzerland and United Kingdom. Jennifer S. Graff's co-authors include Robert W. Dubois, Daniel C. Malone, Mary Brown, James D. Chambers, Peter J. Neumann, Elle Pope, Eleanor M. Perfetto, C. Daniel Mullins, Wim Goettsch and Lucinda Orsini and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Clinical Epidemiology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Jennifer S. Graff

33 papers receiving 470 citations

Peers

Countries citing papers authored by Jennifer S. Graff

Since Specialization

Citations

This map shows the geographic impact of Jennifer S. Graff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer S. Graff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer S. Graff more than expected).

Fields of papers citing papers by Jennifer S. Graff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer S. Graff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer S. Graff. The network helps show where Jennifer S. Graff may publish in the future.

Co-authorship network of co-authors of Jennifer S. Graff

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer S. Graff. A scholar is included among the top collaborators of Jennifer S. Graff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer S. Graff. Jennifer S. Graff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study 2024 ·Journal of Managed Care & Specialty Pharmacy ·Jennifer S. Graff	0
2	Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care 2024 ·Journal of Managed Care & Specialty Pharmacy ·Margaret Johnson, R. L. Bartels, (unknown), Jennifer S. Graff, Jann B. Skelton	0
3	Payer perceptions and use of value assessment tools in the United States 2023 ·Journal of Managed Care & Specialty Pharmacy ·Kimberly Westrich, (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer S. Graff	1
4	Stakeholders find that step therapy should be evidence-based, flexible, and transparent: assessing appropriateness using a consensus approach 2021 ·Journal of Managed Care & Specialty Pharmacy ·(unknown), Robert W. Dubois, Jennifer S. Graff	5
5	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative 2020 ·Value in Health ·Lucinda Orsini, Marc L. Berger, William H. Crown, Gregory W. Daniel, Hans‐Georg Eichler, Wim Goettsch, Jennifer S. Graff, (unknown), Páll Jónsson, (unknown), Brigitta U. Monz, C. Daniel Mullins, Sebastian Schneeweiß, (unknown), Shirley Wang, Richard J. Willke	87
6	Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative 2020 ·Pharmacoepidemiology and Drug Safety ·Lucinda Orsini, Brigitta U. Monz, C. Daniel Mullins, (unknown), Gregory W. Daniel, Hans‐Georg Eichler, Jennifer S. Graff, (unknown), Marc L. Berger, (unknown), Páll Jónsson, Sebastian Schneeweiß, Shirley Wang, William H. Crown, Wim Goettsch, Richard J. Willke	19
7	Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust 2019 ·Patient ·Elisabeth Oehrlein, Jennifer S. Graff, (unknown), Eleanor M. Perfetto	19
8	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage 2019 ·Health Affairs ·James D. Chambers, (unknown), Elle Pope, Jennifer S. Graff, Peter J. Neumann	14
9	PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE 2018 ·International Journal of Technology Assessment in Health Care ·Elisabeth Oehrlein, Jennifer S. Graff, Eleanor M. Perfetto, C. Daniel Mullins, Robert W. Dubois, Chinenye Anyanwu, Eberechukwu Onukwugha	11
10	Specialty Drug Coverage Varies Across Commercial Health Plans In The US 2018 ·Health Affairs ·James D. Chambers, David D. Kim, Elle Pope, Jennifer S. Graff, (unknown), Peter J. Neumann	44
11	Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies? 2017 ·Value in Health ·Daniel C. Malone, Mary Brown, (unknown), (unknown), Jennifer S. Graff	48
12	Data, Data Everywhere, But Access Remains a Big Issue for Researchers: A Review of Access Policies for Publicly-Funded Patient-level Health Care Data in the United States 2016 ·SHILAP Revista de lepidopterología ·Jalpa A. Doshi, Franklin Hendrick, Jennifer S. Graff, Bruce Stuart	13
13	Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges 2016 ·Journal of Managed Care & Specialty Pharmacy ·Eleanor M. Perfetto, Chinenye Anyanwu, (unknown), (unknown), Jennifer S. Graff, (unknown)	9
14	Standards and guidelines for observational studies: quality is in the eye of the beholder 2015 ·Journal of Clinical Epidemiology ·Sally C. Morton, (unknown), Jennifer S. Graff, Robert W. Dubois	28
15	Employer, Insurer, and Industry Perspectives on Patient-Centered Comparative Effectiveness Research 2015 ·Thomas W. Concannon, Dmitry Khodyakov, Virginia Kotzias, (unknown), Jennifer S. Graff, Robert W. Dubois	1
16	The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects 2014 ·Journal of Managed Care Pharmacy ·Daniel C. Malone, Lisa E. Hines, Jennifer S. Graff	7
17	Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research 2012 ·Journal of Comparative Effectiveness Research ·Richard E Gliklich, Michelle B Leavy, Priscilla Velentgas, Nancy A Dreyer, Sean Tunis, Penny Mohr, Donna A. Messner, Rachael Moloney, Swapna Karkare, Robert W. Dubois, Jennifer S. Graff	7
18	Setting Priorities For Comparative Effectiveness Research: From Assessing Public Health Benefits To Being Open With The Public 2011 ·Health Affairs ·Robert W. Dubois, Jennifer S. Graff	15
19	Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study 2008 ·The European Journal of Health Economics ·Douglas C.A. Taylor, Ankur Pandya, David R. Thompson, Paula Chu, Jennifer S. Graff, James Shepherd, Nanette K. Wenger, Heiner Greten, Rafael Carmena, Michael Drummond, Milton C. Weinstein	30
20	Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients 2007 ·Value in Health ·Dan J. Fintel, Amie T. Joyce, Joan Mackell, Jennifer S. Graff, (unknown), Daniel A. Ollendorf	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact